google.com.au/patents/US7674783
- A method for reducing vascular hyperreactivity in vascular muscle cells comprising exposing the vascular muscle cells to an effective amount of a selective estrogen beta receptor agonist that is selected from the group consisting of 5α-androstane-3β,17β-diol, a derivative of 5α-androstane-3β,17β-diol that has estrogen beta receptor agonist activity, epiestriol, and diarylpropionitrile.
- The method of claim 1 wherein the vascular hyperreactivity is manifested by coronary arterial vasospasm.
- The method of claim 1 wherein the vascular hyperreactivity is manifested by hyperreactivity of peripheral arteries.
- The method of claim 1 wherein the estrogen beta receptor agonist is 5α-androstane-3β,17β-diol.
- The method of claim 1 wherein the estrogen beta receptor agonist is a derivative of 5α-androstane-3β,17β-diol that has estrogen beta receptor agonist activity.
- The method of claim 5 wherein the derivative of 5α-androstane-3β,17β-diol is selected from the group consisting of 5α-androstane-3β,17β-diol-3 hemisuccinate, 5α-androstane-3β-diol-17-sulphate sodium salt, 5α-androstan-3β,17β-diol-3-acetate, 5α-androstan-3β,17β-diol-17-acetate, 5α-androstan-3β,17β-diol-diacetate, 5α-androstan-3β,17β-diol-dibenzoate, 5α-androstan-3β,17β-diol-dihemisuccinate, 5α-androstan-3β,17β-diol-diproprionate, and 5α-androstan-3β,17β-diol-17-hexahydrobenzoate.
- The method of claim 1 wherein the estrogen beta receptor agonist is epiestriol.
- The method of claim 1 wherein the estrogen beta receptor agonist is diarylpropionitrile.
- The method of claim 4 wherein the 5α-androstane-3β,17β-diol is administered to a patient and the amount of 5α-androstane-3β,17β-diol that is administered is sufficient to obtain a serum concentration of between 30 and 3000 pg/ml.
- The method of claim 9 wherein the amount of 5α-androstane-3β,17β-diol that is administered is sufficient to obtain a serum concentration of between 30 and 300 pg/ml.
- The method of claim 1 wherein the estrogen beta receptor agonist is administered to a patient in concert with a hormone replacement therapy.
- The method of claim 11 wherein the hormone replacement therapy is selected from the group consisting of estrogen, androgen, and progestin therapy.
- The method of claim 1 wherein the exposure of the vascular muscle cells to the estrogen beta receptor agonist is by administering the estrogen beta receptor agonist by topical application to skin of a patient.
- The method of claim 13 wherein the estrogen beta receptor agonist is in a topical preparation selected from the group consisting of a liquid, cream, gel, lotion, ointment, and transdermal patch.
- The method of claim 1 wherein the exposure of the vascular muscle cells to the estrogen beta receptor agonist is by other than topical administration to skin.
- The method of claim 15 wherein the exposure is by oral, rectal, vaginal, topical, sublingual, nasal, intradermal, inhalation, or sustained implant administration route